Tapinarof cream 1% once daily was evaluated in adults with mild to severe plaque psoriasis in two 12-week pivotal phase 3 trials, PSOARING 1 and 2, and a long-term extension. |
Images of clinical outcomes are important in trials of dermatologic therapies to inform clinical decision-making and enhance patient assessment. |
Here we present patient cases illustrating treatment outcomes including responses meeting the regulatory endpoint of a Physician Global Assessment score of 0 (clear) or 1 (almost clear) and a decrease of at least 2 points from baseline at week 12, as well as patient-reported outcomes, and pre-specified adverse events of special interest (AESIs). |
Tapinarof-treated patients achieving regulatory endpoints also experienced rapid, clinically meaningful improvements, while many patients who did not achieve regulatory endpoints still experienced visible and meaningful improvements in disease activity and quality of life. |
Incidence and severity of AESIs, folliculitis and contact dermatitis, were generally mild or moderate, localized to application sites, and associated with low trial discontinuation rates. |
Open Access 11.09.2023 | Case Series
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials
Erschienen in: Dermatology and Therapy | Ausgabe 10/2023